Maryland Clinical Trials

A listing of Maryland clinical trials actively recruiting patient volunteers.

Filter by Condition
2796 trials found

Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

NCT04579250

Background: Influenza (flu) is a contagious respiratory illness. It is caused by influenza viruses that infect the nose, throat, and lungs. Some people, such as older people, young children, and people with certain health conditions, are at high risk of serious flu complications. Researchers want to test a vaccine to prevent flu. Objective: To see if the H10 Ferritin vaccine is safe and how the body responds to it. Eligibility: Healthy adults ages 18-70. Design: Participants will be scree ...

Conditions: Influenza

Brain-Computer Interface Implant for Severe Communication Disability

NCT04576650

Locked-In Syndrome (LIS) is a devastating condition in which a person has lost the ability to communicate due to motor impairment, while being mentally intact. For people affected by this severe communication impairment, Brain-Computer Interfaces (BCI) may be the only solution that allows these people to start a conversation, ask questions, or request assistance (i.e. self-initiated communication). To-date, spelling was accomplished at a rate of 2-3 letters per minute with a predecessor device ( ...

Conditions: Locked-in Syndrome
Phase: Not Applicable

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

NCT04574583

Background: Combination immunotherapy techniques are being explored to improve responses and enhance benefits in people with cancer. Researchers want to see if this type of treatment can help people with advanced solid tumors. Objective: To find a safe dose of SX-682 in combined treatment with Bintrafusp alfa and BN-CV301 vaccines and to see if this treatment will cause tumors to shrink. Eligibility: Adults age 18 and older with metastatic cancer may be eligible for the first part of the tr ...

Conditions: Metastatic Cancer, Solid Tumors
Phase: Phase 1/2

Clinical Study Spartan COVID-19 V2 System

NCT04575168

This multicentre prospective study will enroll a sufficient number of patients to afford approximately 60 positives and > 40 negatives (as determined by the SOC - Comparator method) in the United States and/or Canada. One to three sites in the United States and/or Canada will participate over an approximate 12-week enrolment period. The actual enrolment period will be dependent upon prevalence of Covid-19. Once positives sample size is achieved, expected SARC-CoV-2 negative subjects will be perm ...

Conditions: Covid19

Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

NCT04573062

In late 2019, a novel coronavirus (COVID-19) appeared in Wuhan, China. The various ways that humans will recover from COVID-19 infections is just starting to be observed and it is clear there will be a wide range of convalescent experiences. This phased protocol is designed to observe and study the convalescence and recoveries from acute COVID-19 infections. Phase A Surveying (Phase A) will enable people in the community that are convalescing from COVID-19 infections to be studied using telepho ...

Conditions: Post-Coronavirus Disease 19

Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries

NCT04572906

NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of a severed nerves in patients between 16 and 65 years of age.

Conditions: Peripheral Nerve Injuries

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

NCT04572243

The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.

Conditions: Epilepsies, Myoclonic

Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease

NCT04569591

Background: Cushing s disease is caused by a pituitary gland tumor. Patients with Cushing s disease suffer obesity, diabetes, osteoporosis, weakness, and hypertension. The cure is surgery to remove the pituitary tumor. Currently, MRI is the best way to find these tumors. But not all tumors can be seen with an MRI. Researchers hope giving the hormone CRH before a PET scan can help make these tumors more visible. Objective: To test whether giving CRH before a PET scan will help find pituitary g ...

Conditions: Cushing's Disease, Pituitary Adenoma
Phase: Not Applicable

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

NCT04568980

The long-term goal is to study the safety and effectiveness of hormonal contraception for women with cystic fibrosis (CF) and contribute to national guidelines that the Cystic Fibrosis Foundation and the Centers for Disease Control and Prevention (CDC) provide to clinicians. The study objectives are to determine whether hormonal contraceptive methods improve overall pulmonary health, worsen CF-related disease or CF liver disease, or are effective against unwanted pregnancy with concomitant CF tr ...

Conditions: Cystic Fibrosis, Contraception

Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD)

NCT04565080

The purpose of this study is to investigate the clinical correlates of the effects of the COVID-19 pandemic on patients with Functional movement disorder (FMD) and Parkinson s Disease (PD). Primary objectives: To evaluate the change in neurological symptoms domain of the survey between pre and post-COVID 19 in FMD and PD patients. Secondary objectives: To evaluate the change in total score of the survey between pre and post COVID 19 in FMD and PD patients To evaluate the change in other symp ...

Conditions: Parkinson's Disease, Functional Movement Disorders, COVID-19

Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans

NCT04565067

Background: The higher death rate from COVID-19 in the older population is associated with low CD8 T cell counts in the blood. Researchers want to learn the status of CD8 T cells specific to SARS-CoV-2 and their changes with aging and in COVID-19. This may help to identify why COVID-19 is particularly lethal in the elderly and help to create an effective vaccine against SARS-CoV-2 in the elderly. Objective: To identify SARS-CoV-2 specific CD8 T cells in humans, and to determine their quantity ...

Conditions: COVID-19

COV2Base-A Rare Disease by COVID Study

NCT04564274

Background: SARS-CoV-2 is the virus that causes COVID. It has caused a global pandemic. Most people have no to mild symptoms. But some people need to be hospitalized, and a small number need critical care. Older age as well as some socio-demographic factors and chronic health conditions may play a role in the severity of COVID. In this study, researchers want to assess population-, disease-, and gene-based risks for features associated with severe SARS-CoV-2 outcomes. Objective: To measure th ...

Conditions: Chronic Health Conditions, Older Age is Associated With Increased Pathogenicity